We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
Emtricitabine/tenofovir
From WikEM
Contents
Administration
- Type: Antiviral (antiretroviral)
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names: Truvada
Adult Dosing
- HIV pre- or post-exposure prophylaxis: 1 tablet (emtricitabine 200 mg/tenofovir 300 mg) PO daily
- HIV infection: 1 tablet daily usually in combination with another agent
Pediatric Dosing
- 17-22kg: Emtricitabine 100 mg/tenofovir 150 mg PO once daily
- 22-28kg: Emtricitabine 133 mg/tenofovir 200 mg PO once daily
- 28-36kg: Emtricitabine 167 mg/tenofovir 250 mg PO once daily
- >35kg: Emtricitabine 200 mg/tenofovir 300 mg PO once daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- CrCl 30-50 mL/min: 1 tablet every 48 hours
- CrCl <30 mL/min: do not use
- CrCl <60 mL/min: do not use for pre-exposure prophylaxis
Contraindications
- Allergy to class/drug
- Monotherapy for HIV infection
- Pre-exposure prophylaxis in patients with unknown HIV status
Adverse Reactions
Serious
- Hepatotoxicity
- Reactivation of hepatitis B
- Immune reconstitution syndrome
- Rhabdomyolysis
- Pancreatitis
- Renal failure
- Fanconi syndrome
Common
- Nausea, diarrhea, abdominal pain
- Rash
- Backache, myalgia, osteopenia
- Lactic acidosis
- Dizziness, fatigue, peripheral neuropathy, headache
- Depression, dream disorder, insomnia
- Pneumonia
Pharmacology
- Half-life: 10-17h
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Both drugs nucleoside analogues that inhibit activity of HIV-1 reverse transcriptase
